Targeting several CAG expansion diseases by a single antisense oligonucleotide

Area of Science:

• Neuroscience
• Genetics
• Molecular Biology

Background:

• Huntington's disease is a fatal neurodegenerative disorder caused by expanded CAG repeats in the HTT gene.
• The expanded polyglutamine tract leads to toxic protein aggregation, driving disease pathology.
• Currently, no effective therapies exist for Huntington's disease.

Purpose of the Study:

• To investigate the therapeutic potential of modified antisense oligonucleotides (ASOs) targeting expanded polyglutamine repeats.
• To assess the efficacy of ASOs in reducing mutant huntingtin transcript and protein levels.
• To explore the applicability of this ASO approach to other polyglutamine expansion disorders.

Main Methods:

• Utilized modified 2'-O-methyl phosphorothioate (CUG)n triplet-repeat antisense oligonucleotides.
• Tested ASO efficacy in patient-derived fibroblasts and lymphoblasts for Huntington's disease.
• Evaluated ASO impact on mutant ataxin-1, ataxin-3, and atrophin-1 mRNA levels in related disorders.

Main Results:

• A specific ASO, (CUG)(7), effectively reduced mutant huntingtin transcript and protein in Huntington's disease cells.
• The (CUG)(7) ASO also decreased mutant ataxin-1 and ataxin-3 mRNA levels.
• This ASO demonstrated efficacy in reducing atrophin-1 in dentatorubral-pallidoluysian atrophy cells.

Conclusions:

• Modified antisense oligonucleotides represent a promising therapeutic strategy for Huntington's disease.
• The developed ASO therapy shows potential for treating a range of polyglutamine expansion disorders.
• This research opens new avenues for tackling neurodegenerative diseases caused by repeat expansions.